GB202206353D0 - Treatment of cervical dystonia - Google Patents

Treatment of cervical dystonia

Info

Publication number
GB202206353D0
GB202206353D0 GBGB2206353.1A GB202206353A GB202206353D0 GB 202206353 D0 GB202206353 D0 GB 202206353D0 GB 202206353 A GB202206353 A GB 202206353A GB 202206353 D0 GB202206353 D0 GB 202206353D0
Authority
GB
United Kingdom
Prior art keywords
treatment
cervical dystonia
dystonia
cervical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2206353.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Priority to GBGB2206353.1A priority Critical patent/GB202206353D0/en
Publication of GB202206353D0 publication Critical patent/GB202206353D0/en
Priority to AU2023262641A priority patent/AU2023262641A1/en
Priority to CA3245899A priority patent/CA3245899A1/en
Priority to US18/851,566 priority patent/US20250302928A1/en
Priority to JP2024563502A priority patent/JP2025514275A/ja
Priority to EP23715221.0A priority patent/EP4514378A1/en
Priority to KR1020247039344A priority patent/KR20250004869A/ko
Priority to PCT/GB2023/050742 priority patent/WO2023209326A1/en
Priority to CN202380036879.2A priority patent/CN119110728A/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB2206353.1A 2022-04-29 2022-04-29 Treatment of cervical dystonia Ceased GB202206353D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB2206353.1A GB202206353D0 (en) 2022-04-29 2022-04-29 Treatment of cervical dystonia
AU2023262641A AU2023262641A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia
CA3245899A CA3245899A1 (en) 2022-04-29 2023-03-23 TREATMENT OF CERVICAL DYSTONIA
US18/851,566 US20250302928A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia
JP2024563502A JP2025514275A (ja) 2022-04-29 2023-03-23 頸部ジストニアの治療
EP23715221.0A EP4514378A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia
KR1020247039344A KR20250004869A (ko) 2022-04-29 2023-03-23 경부 이상긴장증의 치료
PCT/GB2023/050742 WO2023209326A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia
CN202380036879.2A CN119110728A (zh) 2022-04-29 2023-03-23 颈肌张力障碍的治疗

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2206353.1A GB202206353D0 (en) 2022-04-29 2022-04-29 Treatment of cervical dystonia

Publications (1)

Publication Number Publication Date
GB202206353D0 true GB202206353D0 (en) 2022-06-15

Family

ID=81943814

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2206353.1A Ceased GB202206353D0 (en) 2022-04-29 2022-04-29 Treatment of cervical dystonia

Country Status (9)

Country Link
US (1) US20250302928A1 (https=)
EP (1) EP4514378A1 (https=)
JP (1) JP2025514275A (https=)
KR (1) KR20250004869A (https=)
CN (1) CN119110728A (https=)
AU (1) AU2023262641A1 (https=)
CA (1) CA3245899A1 (https=)
GB (1) GB202206353D0 (https=)
WO (1) WO2023209326A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
CA2758274C (en) 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP3162894B1 (en) 2011-05-19 2024-01-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
JP2024534384A (ja) * 2021-09-16 2024-09-20 イプセン バイオファーム リミテッド 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ

Also Published As

Publication number Publication date
JP2025514275A (ja) 2025-05-02
CA3245899A1 (en) 2023-11-02
KR20250004869A (ko) 2025-01-08
AU2023262641A1 (en) 2024-10-10
CN119110728A (zh) 2024-12-10
WO2023209326A1 (en) 2023-11-02
US20250302928A1 (en) 2025-10-02
EP4514378A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
IL315503A (en) Treatment methods
IL320711A (en) Treatment methods
GB202206353D0 (en) Treatment of cervical dystonia
GB202201824D0 (en) Methods of treatment
GB202206357D0 (en) Treatment of cervical dystonia
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
HK40117553A (en) Treatment of cervical dystonia
GB202001353D0 (en) Treatment of skin conditions
GB202315695D0 (en) TReatment of cariomyopathy
GB202307686D0 (en) Treatment of conditions
GB202212506D0 (en) Treatment of covid-19
IL325944A (en) Treatment methods
GB202206359D0 (en) Treatment of pain
GB202101251D0 (en) Treatment of conditions
GB202116774D0 (en) Treatment of pain
HK40112431A (en) Treatment of visceral pain
GB202011055D0 (en) Treatment of post-operative pain
HK40117401A (en) Treatment of pain
HK40130651A (en) Treatment of opiod-induced pain
GB202118007D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)